INNOVENT BIO (01801.HK)'s total product revenue for 2024 amounted to more than RMB8.2 billion, representing a robust YoY growth of over 40%, according to INNOVENT BIO's announcement. In 4Q24, the ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

In America, heart disease is the No. 1 killer of men and women and the leading cause of death for people of most racial and ...

Researchers have found in Phase 3 LIBerate-HoFH trial that Lerodalcibep, a third-generation PCSK9 inhibitor, showed similar ...

Obesity significantly impacts cardiovascular health, increasing risks such as left ventricular hypertrophy, atherosclerosis, ...

Researchers have found that the mutations driving it may stem from a commonly inherited variant of the PCSK9 ... Nov. 22, 2024 — Researchers have discovered how the interplay between a key ...

Both types are effective at managing cholesterol, but researchers have uncovered some surprising side effects. Weight Gain: ...

Homozygous familial hypercholesterolaemia affects approximately 30 000 individuals worldwide.1,2 Patients have untreated high ...

During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why biotech in China is booming as well as therapeutic areas where he sees promising science.

Medications called estrogen blockers are among the treatment options for those with ... One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone therapy ...

Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri 63110, United States ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.